What drives mortality among HIV patients in a conflict setting? A prospective cohort study in the Central African Republic

Table 1 Characteristics of the 1631 HIV-positive patients enrolled in the Zemio HIV cohort, Central African Republic from October 2011–May 2017. Interquartile range = IQR, ART = antiretroviral therapy, OIs = opportunistic infections. Loss to follow up is defined as patients not present for an appointment > 12 months before the end of the program

Total patients enrolled in the Zemio HIV cohort	1631 (4107 person-years at risk)
Patients enrolled on ART	1491/1631 (91.4%)
Female patients	1147/1631 (70.3%)
Median age at first appointment (IQR)	29 years (22, 37)
Deaths	148
Loss to follow up	183
CD4 cell count/μl, baseline (IQR), n = 1017	268 (148, 427)
CD4 cell count/μl, 6 months (IQR), n = 442	403 (240, 634)
CD4 cell count/μl, 12 months (IQR), n = 321	433 (264, 636)
Clinical Stage 1 OIs at baseline	241/1628 (14.8%)
Clinical Stage 2 OIs at baseline	403/1628 (24.7%)
Clinical Stage 3 OIs at baseline	789/1628 (48.5%)
Clinical Stage 4 OIs at baseline	195/1628 (12.0%)
Occupation: Infants/ Pupil / Student	148/1628 (9.1%)
Occupation: Farmers / Fishermen / Domestic	1272/1628 (78.1%)
Occupation: Small commerce	139/1628 (8.5%)
Occupation: Civil servant/ official	26/1628 (1.6%)
Occupation: Other /not recorded	43/1628 (2.6%)

ISSN: 1752-1505